Oramed Pharmaceuticl (ORMP) 7.10 $ORMP
Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes
PR Newswire - Fri Oct 31, 7:25AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP)(http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announces that the company will host a conference call to discuss the clinical results from its Phase IIa clinical trial of ORMD-0801, the company's proprietary oral insulin capsules, to treat type 1 diabetes on Monday, November 3, 2014 at 10:00 a.m. Eastern time.
ORMP: 7.10 (+0.11)
Oramed to Present at the FireRock Annual Micro-Cap Conference
PR Newswire - Fri Oct 24, 7:25AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company's CEO, Nadav Kidron will present at FireRock Capital's Micro-Cap Conference.
ORMP: 7.10 (+0.11)
Oramed Pharmaceuticals announces positive top-line clinical results from Phase IIa clinical trial of ORMD-0801 for treatment of type 1 diabetes
M2 - Wed Oct 22, 10:39AM CDT
Oramed Pharmaceuticals Inc (NASDAQCM: ORMP), a clinical-stage pharmaceutical company that developms oral drug delivery systems, announce on Wednesday that its Phase IIa clinical trial of ORMD-0801, its proprietary oral insulin capsules to treat type 1 diabetes, has achieved positive top-line clinical results.
ORMP: 7.10 (+0.11)
Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes
PR Newswire - Wed Oct 22, 7:29AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today reported positive top-line clinical results from its Phase IIa clinical trial of ORMD-0801, the company's proprietary oral insulin capsules, to treat type 1 diabetes. The trial was conducted in the United States under a U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) protocol.
ORMP: 7.10 (+0.11)
Nasdaq stocks posting largest percentage increases
AP - Tue Sep 30, 12:20PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
CENX: 28.14 (+0.28), TRVN: 5.91 (+0.02), UNXL: 5.31 (+0.77), ICEL: 7.53 (+0.03), CLVS: 58.31 (-0.26), TIBX: 23.62 (+0.12), ORMP: 7.10 (+0.11), AMBI: 15.34 (-0.12), MOVE: 20.96 (-0.01), SAJA: 5.79 (-0.61)
Oramed to Present at Family Office & Wealth Management Conference
PR Newswire - Mon Sep 15, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the Company's CEO, Nadav Kidron will present at DC Finance's Family Office & Wealth Management Annual Conference.
ORMP: 7.10 (+0.11)
Oramed's Insulin Pill Superior to New Diabetes Drugs Gaining Approval
ACCESSWIRE - Thu Sep 11, 7:01AM CDT
Los Angeles, CA / September 11, 2014 / Pharmaceutical companies are adept at rolling out new classes of drugs, despite potential harmful side effects, and Eli Lilly and Co. (LLY:NYSE) is no exception. Just recently, Lilly began selling Jardiance, a once-daily tablet for Type 2 diabetics, a 'flozin', with an onerous side effect profile that rivals medications like Bristol-Myers Squibb's (BMY:NYSE) anti-blood clot drug Plavix which has caused internal bleeding that results in vomiting coagulated blood. Medicine for diabetics, one of the largest populations of sick patients in the US, should look to more natural means for bringing insulin into the body. Oramed Pharmaceuticals, Inc. (ORMP:NASDAQ) offers a potential remedy and has been making good progress in clinical trials, as outlined below.
ORMP: 7.10 (+0.11), LLY: 66.60 (-0.36), BMY: 58.32 (-0.14)
Oramed to Present at Upcoming Conferences
PR Newswire - Wed Sep 03, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the Company's CEO, Nadav Kidron will present at the following conferences in September 2014:
ORMP: 7.10 (+0.11)
Competitor Analysis: GLP-1 Receptor Agonists Development Pipeline Report 2014
M2 - Tue Aug 19, 9:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7d4zkt/competitor) has announced the addition of the "Competitor Analysis: GLP-1 Receptor Agonists" report to their offering. The Competitive Intelligence Report Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as of August 2014 provides a competitor analysis in the development pipeline of novel GLP-1 analogs and GLP-1 receptor agonists and co-agonists for treatment of diabetes and obesity. In the year 2013, the marketed daily and weekly GLP-1 agonists achieved combined sales of US$ 3,231 mln representing 6.3% of the total diabetes care market. The leading GLP-1 analog Victoza held 69% of the GLP-1 market and is further expanding its predominance in the first half of 2014 with a 72% share of the GLP-1 market which grew to 6.9% of the total diabetes care market. The increasingly attractive GLP-1 market provides an opportunity of application of new technologies to prolong the half-life of GLP-1 analogs as well as finding co-agonists of GLP-1 receptor with additional receptors, such as insulin, glucagon, GIP, gastrin or GLP-1. In addition, expansion of indications for GLP-1 analogs will contribute to further expand the GLP-1 market. The report provides a compilation of current active projects in research and development of novel GLP-1 analogs and GLP-1 receptor agonists as well as co-agonists. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage - Additional comments with a hyperlink leading to the source of information. Key Topics Covered: 1. Selective GLP-1 Analogs for Metabolic Diseases - 2013 Sales of GLP-1 Analogs - Short-Acting Injectable GLP-1 Analogs - Long-Acting Injectable GLP-1 Analogs - Very Long-Acting Injectable GLP-1 Analogs - Oral Peptide-Based GLP-1 Analogs - Other Non-Injectable Peptide-Based GLP-1 Analogs - Oral Small Molecule GLP-1 Receptor Agonists 2. Selective GLP-1 Analogs for Non-Metabolic Diseases 3. Dual Target GLP-1 Analogs - GLP-1 and Insulin - GLP-1 and Glucagon - GLP-1 and GIP - GLP-1 and Gastrin/CCKB - GLP-1 and GLP-2 4. Corporate GLP-1 Receptor Agonist R&D Pipelines Companies Mentioned - Addex Pharmaceuticals - Amylin Pharmaceuticals - Arisaph Pharmaceuticals - Arisgen - Ascendis Pharma (Complex Biosystems) - Bio-ker - Biocompatibles International - ConjuChem - Dong-A Pharmaceutical - Eli Lilly - Emisphere Technologies - Faust Pharmaceuticals - GlaxoSmithKline - Hanmi Pharmaceuticals - Ipse - Mannkind - MDRNA (ex Nastech Pharmaceuticals) - Modigene - Novo Nordisk - OctoPlus - Oramed Pharmaceuticals - Pfizer - Proxima Concepts - Roche (& Chugai) - Rose Pharmaceuticals (ex Gastrotech) - Sanofi-Aventis - Teijin - Transition Therapeutics - TransTech Pharma - Unigene For more information visit http://www.researchandmarkets.com/research/7d4zkt/competitor
NVO: 43.69 (-0.10), ORMP: 7.10 (+0.11), TTHI: 6.43 (-0.01), LLY: 66.60 (-0.36), GSK: 44.91 (+0.16)
Oramed Granted Patent in Spain for Oral Administration of Insulin
PR Newswire - Tue Aug 19, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Intellectual Property Department of Spain has granted the Company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Proteins."
ORMP: 7.10 (+0.11)
Oramed Pharmaceuticals treats last patient with ORMD-0801 in Phase IIa trial for type 1 diabetes
M2 - Fri Aug 08, 5:57AM CDT
Pharmaceutical company Oramed Pharmaceuticals (NasdaqCM:ORMP) reported on Thursday the treatment of the last type 1 diabetes patient under its Phase IIa clinical trial of ORMD-0801.
ORMP: 7.10 (+0.11)
Oramed Pharmaceuticals Reports Last Patient Out in Phase IIa Trial for ORMD-0801 in Type 1 Diabetes
PR Newswire - Thu Aug 07, 7:20AM CDT
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today reports that the last patient has completed treatment in its Phase IIa clinical trial of ORMD-0801, the Company's proprietary oral insulin capsule, to treat type 1 diabetes, and top-line data is expected to be reported in the fourth quarter of 2014. The trial was conducted in the United States under a Food and Drug Administration Investigational New Drug protocol.
ORMP: 7.10 (+0.11)
Oramed Pharmaceuticals to Present at the BIO International Convention in San Diego
PR Newswire - Mon Jun 23, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Chief Executive Officer, Nadav Kidron, will present at the 2014 BIO International Convention. This year's global event for biotechnology will take place on June 23-26 at the San Diego Convention Center in San Diego, California.
ORMP: 7.10 (+0.11)
A Speculative Biotech Catalyst Trade: ORMP
at The Street - Fri Mar 28, 8:23AM CDT
This beaten-down biotech stock could be ripe for a rebound.
ORMP: 7.10 (+0.11), IBB: 290.14 (-3.18)
Oramed Pharmaceuticals Announces First Patient Enrolled in a US Phase 2a Trial for ORMD-0801 in Treatment of Type 1 Diabetes
PR Newswire - Thu Mar 27, 7:45AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the first patient has been enrolled in its U.S. Phase 2a trial for its orally ingestible insulin capsule, ORMD-0801, in the treatment of type 1 diabetes (T1DM).
ORMP: 7.10 (+0.11)
5 Stocks With Big Insider Buying
at The Street - Wed Mar 26, 11:43AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
EQIX: 214.03 (-0.84), ORMP: 7.10 (+0.11), NVAX: 4.95 (-0.20), CHK: 23.41 (+0.65), AGCO: 45.55 (+0.91)
These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
at The Street - Tue Mar 25, 1:35PM CDT
Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.
AGEN: 3.02 (-0.03), RPTP: 10.15 (+0.47), ORMP: 7.10 (+0.11), NVAX: 4.95 (-0.20), GERN: 2.33 (-0.07), CLDX: 13.42 (-0.06), NLNK: 32.15 (-2.54), CYTR: 2.87 (-0.06), GALE: 1.95 (-0.09)
Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes
PR Newswire - Fri Oct 31, 7:25AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP)(http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announces that the company will host a conference call to discuss the clinical results from its Phase IIa clinical trial of ORMD-0801, the company's proprietary oral insulin capsules, to treat type 1 diabetes on Monday, November 3, 2014 at 10:00 a.m. Eastern time.
ORMP: 7.10 (+0.11)
Oramed to Present at the FireRock Annual Micro-Cap Conference
PR Newswire - Fri Oct 24, 7:25AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company's CEO, Nadav Kidron will present at FireRock Capital's Micro-Cap Conference.
ORMP: 7.10 (+0.11)
Oramed Pharmaceuticals announces positive top-line clinical results from Phase IIa clinical trial of ORMD-0801 for treatment of type 1 diabetes
M2 - Wed Oct 22, 10:39AM CDT
Oramed Pharmaceuticals Inc (NASDAQCM: ORMP), a clinical-stage pharmaceutical company that developms oral drug delivery systems, announce on Wednesday that its Phase IIa clinical trial of ORMD-0801, its proprietary oral insulin capsules to treat type 1 diabetes, has achieved positive top-line clinical results.
ORMP: 7.10 (+0.11)
Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes
PR Newswire - Wed Oct 22, 7:29AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today reported positive top-line clinical results from its Phase IIa clinical trial of ORMD-0801, the company's proprietary oral insulin capsules, to treat type 1 diabetes. The trial was conducted in the United States under a U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) protocol.
ORMP: 7.10 (+0.11)
Nasdaq stocks posting largest percentage increases
AP - Tue Sep 30, 12:20PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
CENX: 28.14 (+0.28), TRVN: 5.91 (+0.02), UNXL: 5.31 (+0.77), ICEL: 7.53 (+0.03), CLVS: 58.31 (-0.26), TIBX: 23.62 (+0.12), ORMP: 7.10 (+0.11), AMBI: 15.34 (-0.12), MOVE: 20.96 (-0.01), SAJA: 5.79 (-0.61)
Oramed to Present at Family Office & Wealth Management Conference
PR Newswire - Mon Sep 15, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the Company's CEO, Nadav Kidron will present at DC Finance's Family Office & Wealth Management Annual Conference.
ORMP: 7.10 (+0.11)
Oramed's Insulin Pill Superior to New Diabetes Drugs Gaining Approval
ACCESSWIRE - Thu Sep 11, 7:01AM CDT
Los Angeles, CA / September 11, 2014 / Pharmaceutical companies are adept at rolling out new classes of drugs, despite potential harmful side effects, and Eli Lilly and Co. (LLY:NYSE) is no exception. Just recently, Lilly began selling Jardiance, a once-daily tablet for Type 2 diabetics, a 'flozin', with an onerous side effect profile that rivals medications like Bristol-Myers Squibb's (BMY:NYSE) anti-blood clot drug Plavix which has caused internal bleeding that results in vomiting coagulated blood. Medicine for diabetics, one of the largest populations of sick patients in the US, should look to more natural means for bringing insulin into the body. Oramed Pharmaceuticals, Inc. (ORMP:NASDAQ) offers a potential remedy and has been making good progress in clinical trials, as outlined below.
ORMP: 7.10 (+0.11), LLY: 66.60 (-0.36), BMY: 58.32 (-0.14)
Oramed to Present at Upcoming Conferences
PR Newswire - Wed Sep 03, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the Company's CEO, Nadav Kidron will present at the following conferences in September 2014:
ORMP: 7.10 (+0.11)
Competitor Analysis: GLP-1 Receptor Agonists Development Pipeline Report 2014
M2 - Tue Aug 19, 9:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7d4zkt/competitor) has announced the addition of the "Competitor Analysis: GLP-1 Receptor Agonists" report to their offering. The Competitive Intelligence Report Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as of August 2014 provides a competitor analysis in the development pipeline of novel GLP-1 analogs and GLP-1 receptor agonists and co-agonists for treatment of diabetes and obesity. In the year 2013, the marketed daily and weekly GLP-1 agonists achieved combined sales of US$ 3,231 mln representing 6.3% of the total diabetes care market. The leading GLP-1 analog Victoza held 69% of the GLP-1 market and is further expanding its predominance in the first half of 2014 with a 72% share of the GLP-1 market which grew to 6.9% of the total diabetes care market. The increasingly attractive GLP-1 market provides an opportunity of application of new technologies to prolong the half-life of GLP-1 analogs as well as finding co-agonists of GLP-1 receptor with additional receptors, such as insulin, glucagon, GIP, gastrin or GLP-1. In addition, expansion of indications for GLP-1 analogs will contribute to further expand the GLP-1 market. The report provides a compilation of current active projects in research and development of novel GLP-1 analogs and GLP-1 receptor agonists as well as co-agonists. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage - Additional comments with a hyperlink leading to the source of information. Key Topics Covered: 1. Selective GLP-1 Analogs for Metabolic Diseases - 2013 Sales of GLP-1 Analogs - Short-Acting Injectable GLP-1 Analogs - Long-Acting Injectable GLP-1 Analogs - Very Long-Acting Injectable GLP-1 Analogs - Oral Peptide-Based GLP-1 Analogs - Other Non-Injectable Peptide-Based GLP-1 Analogs - Oral Small Molecule GLP-1 Receptor Agonists 2. Selective GLP-1 Analogs for Non-Metabolic Diseases 3. Dual Target GLP-1 Analogs - GLP-1 and Insulin - GLP-1 and Glucagon - GLP-1 and GIP - GLP-1 and Gastrin/CCKB - GLP-1 and GLP-2 4. Corporate GLP-1 Receptor Agonist R&D Pipelines Companies Mentioned - Addex Pharmaceuticals - Amylin Pharmaceuticals - Arisaph Pharmaceuticals - Arisgen - Ascendis Pharma (Complex Biosystems) - Bio-ker - Biocompatibles International - ConjuChem - Dong-A Pharmaceutical - Eli Lilly - Emisphere Technologies - Faust Pharmaceuticals - GlaxoSmithKline - Hanmi Pharmaceuticals - Ipse - Mannkind - MDRNA (ex Nastech Pharmaceuticals) - Modigene - Novo Nordisk - OctoPlus - Oramed Pharmaceuticals - Pfizer - Proxima Concepts - Roche (& Chugai) - Rose Pharmaceuticals (ex Gastrotech) - Sanofi-Aventis - Teijin - Transition Therapeutics - TransTech Pharma - Unigene For more information visit http://www.researchandmarkets.com/research/7d4zkt/competitor
NVO: 43.69 (-0.10), ORMP: 7.10 (+0.11), TTHI: 6.43 (-0.01), LLY: 66.60 (-0.36), GSK: 44.91 (+0.16)
Oramed Granted Patent in Spain for Oral Administration of Insulin
PR Newswire - Tue Aug 19, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Intellectual Property Department of Spain has granted the Company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Proteins."
ORMP: 7.10 (+0.11)
Oramed Pharmaceuticals treats last patient with ORMD-0801 in Phase IIa trial for type 1 diabetes
M2 - Fri Aug 08, 5:57AM CDT
Pharmaceutical company Oramed Pharmaceuticals (NasdaqCM:ORMP) reported on Thursday the treatment of the last type 1 diabetes patient under its Phase IIa clinical trial of ORMD-0801.
ORMP: 7.10 (+0.11)
Oramed Pharmaceuticals Reports Last Patient Out in Phase IIa Trial for ORMD-0801 in Type 1 Diabetes
PR Newswire - Thu Aug 07, 7:20AM CDT
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today reports that the last patient has completed treatment in its Phase IIa clinical trial of ORMD-0801, the Company's proprietary oral insulin capsule, to treat type 1 diabetes, and top-line data is expected to be reported in the fourth quarter of 2014. The trial was conducted in the United States under a Food and Drug Administration Investigational New Drug protocol.
ORMP: 7.10 (+0.11)
Oramed Pharmaceuticals to Present at the BIO International Convention in San Diego
PR Newswire - Mon Jun 23, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Chief Executive Officer, Nadav Kidron, will present at the 2014 BIO International Convention. This year's global event for biotechnology will take place on June 23-26 at the San Diego Convention Center in San Diego, California.
ORMP: 7.10 (+0.11)
A Speculative Biotech Catalyst Trade: ORMP
at The Street - Fri Mar 28, 8:23AM CDT
This beaten-down biotech stock could be ripe for a rebound.
ORMP: 7.10 (+0.11), IBB: 290.14 (-3.18)
Oramed Pharmaceuticals Announces First Patient Enrolled in a US Phase 2a Trial for ORMD-0801 in Treatment of Type 1 Diabetes
PR Newswire - Thu Mar 27, 7:45AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the first patient has been enrolled in its U.S. Phase 2a trial for its orally ingestible insulin capsule, ORMD-0801, in the treatment of type 1 diabetes (T1DM).
ORMP: 7.10 (+0.11)
5 Stocks With Big Insider Buying
at The Street - Wed Mar 26, 11:43AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
EQIX: 214.03 (-0.84), ORMP: 7.10 (+0.11), NVAX: 4.95 (-0.20), CHK: 23.41 (+0.65), AGCO: 45.55 (+0.91)
These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
at The Street - Tue Mar 25, 1:35PM CDT
Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.
AGEN: 3.02 (-0.03), RPTP: 10.15 (+0.47), ORMP: 7.10 (+0.11), NVAX: 4.95 (-0.20), GERN: 2.33 (-0.07), CLDX: 13.42 (-0.06), NLNK: 32.15 (-2.54), CYTR: 2.87 (-0.06), GALE: 1.95 (-0.09)
